Jillian Smith

3.3k citations

16 papers · 2.4k · 2 hit papers · h-index 8

Impact in

Oncology top 1%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
Immunology top 2%
- Immune Cell Function and Interaction
- Immune cells in cancer
- Immunotherapy and Immune Responses

Papers in

Physiology 6
- Alzheimer's disease research and treatments 6
Neurology 4
- Myasthenia Gravis and Thymoma 2
- Autoimmune Neurological Disorders and Treatments 1

Co-authors: Crystal L. Mackall (3 shared papers)Rosandra N. Kaplan (2 shared papers)Rimas J. Orentas (2 shared papers)Adrienne H. Long (2 shared papers)Alec J. Walker (2 shared papers)Steven L. Highfill (2 shared papers)Yongzhi Cui (2 shared papers)Meera Murgai (1 shared paper)
Journals: Alzheimer s & Dementia (5 papers)Neurology (4 papers)Cancer Immunology Research (1 paper)Nature Medicine (1 paper)Journal of Clinical Pathology (1 paper)
Partner nations: United States Switzerland United Kingdom

In The Last Decade

Jillian Smith

15 papers receiving 2.3k citations

Jillian Smith's Hit Papers

align trajectories log scale

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors 2015 · 1.3k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 Nature Medicine
2014 Science Translational Medicine

Peers

Countries citing papers authored by Jillian Smith

Since Specialization

Citations

This map shows the geographic impact of Jillian Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jillian Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jillian Smith more than expected).

Fields of papers citing papers by Jillian Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jillian Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jillian Smith. The network helps show where Jillian Smith may publish in the future.

Co-authors

The 25 scholars most cited alongside Jillian Smith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jillian Smith Line = papers co-authored together Jillian Smith links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work
1	4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors Nature Medicine ·Adrienne H. Long, Waleed Haso, Jack F. Shern, Kelsey M. Wanhainen, Meera Murgai, Maria Ingaramo, Jillian Smith, Alec J. Walker, M. Eric Kohler, Vikas R Venkateshwara, Rosandra N. Kaplan, George H. Patterson, Terry J. Fry, Rimas J. Orentas, Crystal L. Mackall Hit paper breakdown →	2015	1301
2	Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy Science Translational Medicine ·Steven L. Highfill, Yongzhi Cui, Amber Giles, Jillian Smith, Hua Zhang, Elizabeth M. Morse, Rosandra N. Kaplan, Crystal L. Mackall Hit paper breakdown →	2014	624
3	Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas Cancer Immunology Research ·Adrienne H. Long, Steven L. Highfill, Yongzhi Cui, Jillian Smith, Alec J. Walker, Sneha Ramakrishna, Rana El-Etriby, Susana Galli, Maria Tsokos, Rimas J. Orentas, Crystal L. Mackall	2016	276
4	Volatile organic compounds in the breath of patients with schizophrenia. Journal of Clinical Pathology ·Michael Phillips, Gerald A. Ring Erickson, M Sabas, Jillian Smith, Joel Greenberg	1995	56
5	Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks Journal of Alzheimer s Disease ·Heather Guthrie, Lawrence S. Honig, Helen Lin, Kaycee M. Sink, Kathleen Blondeau, Angelica Quartino, Michael Dolton, Montserrat Carrasco‐Triguero, Qinshu Lian, Tobias Bittner, David Clayton, Jillian Smith, Susanne Ostrowitzki	2020	46
6	Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial The Lancet Neurology ·Ali A. Habib, Chongbo Zhao, Inmaculada Aban, Marcondes C. França, Jorge Gustavo José, Gerd Meyer zu Hörste, Elzbieta Klimiec, Michael Pulley, Darío Tavolini, Petranka Krumova, Siân Lennon‐Chrimes, Jillian Smith, Gian‐Andrea Thanei, Kathleen Blondeau, Ivana Vodopivec, Gil I. Wolfe, Hiroyuki Murai	2025	16
7	P2‐003: Clinical Trial Design of Cread: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Study to Evaluate Crenezumab Treatment in Patients with Prodromal‐To‐Mild Alzheimer’s Disease Alzheimer s & Dementia ·Thomas Blaettler, Janice Smith, Jillian Smith, Robert Paul, Veronica Asnaghi, Reina N. Fuji, Angelica Quartino, Lee Honigberg, Michael Rabbia, Susan Yule, Susanne Ostrowitzki, Paulo Fontoura	2016	13
8	Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO) Frontiers in Neurology ·Soon‐Tae Lee, Hesham Abboud, Sarosh R. Irani, Hideto Nakajima, Amanda L. Piquet, Sean J. Pittock, E. Ann Yeh, Jiawei Wang, Sharmila Rajan, James Overell, Jillian Smith, Jane St Lambert, Muna El-Khairi, М.Э. Гафарова, Jeffrey M. Gelfand	2024	9
9	Long-Term Safety And Tolerability Of Escalating Doses Of Crenezumab In Patients With Mild-To-Moderate Alzheimer’s Disease (P6.083) Neurology ·Veronica Asnaghi, Helen Lin, Michael Rabbia, Susanne Ostrowitzki, Jillian Smith, William C. Cho	2017	4
10	[O2–17–06]: SAFETY AND TOLERABILITY OF CRENEZUMAB IN MILD‐TO‐MODERATE AD PATIENTS TREATED WITH ESCALATING DOSES FOR UP TO 25 MONTHS Alzheimer s & Dementia ·Veronica Asnaghi, Helen Lin, Nan Hu, Jillian Smith, Yong‐Yeon Cho, Susanne Ostrowitzki	2017	3
11	Safety, Tolerability and Pharmacokinetics of Crenezumab in Mild-to-Moderate AD Patients Treated with Escalating Doses for up to 32.3 Months (P6.182) Neurology ·Helen Lin, Andres Schneider, Angelica Quartino, Tobias Bittner, Nan Hu, Jillian Smith, Yong‐Yeon Cho, Susanne Ostrowitzki	2018	3
12	O1‐02‐04: BASELINE CHARACTERICS FROM A PHASE 3 TRIAL OF CRENEZUMAB IN PRODROMAL TO MILD ALZHEIMER'S DISEASE (CREAD) Alzheimer s & Dementia ·Helen Lin, Susanne Ostrowitzki, Kaycee M. Sink, Laurie Millar, Francis Warren, Jillian Smith, Andres Schneider, Reina N. Fuji, Angelica Quartino, Howard Mackey, Michael Rabbia, Susan Yule, Paulo Fontoura, Rachelle S. Doody	2018	2
13	P1‐046: BASELINE CHARACTERISTICS FROM CREAD2: A PHASE III TRIAL OF CRENEZUMAB IN EARLY (PRODROMAL‐TO‐MILD) ALZHEIMER'S DISEASE Alzheimer s & Dementia ·Kaycee M. Sink, Francis Warren, Jillian Smith, Andres Schneider, Reina N. Fuji, Angelica Quartino, Howard Mackey, Michael Rabbia, Susan Yule, Paulo Fontoura, Rachelle S. Doody, Susanne Ostrowitzki	2019	2
14	Baseline Characteristics from a Phase III Trial of Crenezumab in Early (Prodromal-to-Mild) Alzheimer’s Disease (CREAD) (P4.1-002) Neurology ·Kaycee M. Sink, Susanne Ostrowitzki, Laurie Millar, Francis Warren, Helen Lin, Jillian Smith, Andres Schneider, Reina N. Fuji, Angelica Quartino, Howard Mackey, Michael Rabbia, Susan Yule, Paulo Fontoura, Rachelle S. Doody	2019	2
15	LUMINESCE, a Phase 3 Study of Satralizumab in Generalized Myasthenia Gravis (gMG): Baseline Characteristics (P10-11.015) Neurology ·Ali A. Habib, Chongbo Zhao, Inmaculada Aban, Marcondes C. França, Jorge Gustavo José, Gerd Meyer zu Hörste, Elzbieta Klimiec, Michael Pulley, Darío Tavolini, Petranka Krumova, Siân Lennon‐Chrimes, Jillian Smith, Gian‐Andrea Thanei, Ivana Vodopivec, Gil I. Wolfe, Hiroyuki Murai	2024	1
16	P4‐209: A PUBLIC RESOURCE OF BASELINE DATA FROM THE API AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE COLOMBIA TRIAL Alzheimer s & Dementia ·Eric M. Reiman, Kaycee M. Sink, Nan Hu, Heather Guthrie, Jillian Smith, William C. Cho, Katie L. Knoll, Jessica B. Langbaum, Ronald G. Thomas, Arthur W. Toga, Kewei Chen, Connie A. Boker, Sergio Álvarez, Yakeel T. Quiroz, Silvia Ríos Romenets, Francisco Lopera, Pierre N. Tariot, (unknown)	2018	0

About Jillian Smith

Jillian Smith is a scholar working on Physiology, Neurology, Oncology, Pharmacology and Immunology, having authored 16 papers that have together received 2.4k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (6 papers), Cholinesterase and Neurodegenerative Diseases (3 papers), Immune Cell Function and Interaction (3 papers), Myasthenia Gravis and Thymoma (2 papers), CAR-T cell therapy research (2 papers), Autoimmune Neurological Disorders and Treatments (1 paper), T-cell and B-cell Immunology (1 paper) and Dementia and Cognitive Impairment Research (1 paper). The work is most often cited by research in Oncology (1.8k citations), Immunology (1.0k citations), Genetics (362 citations), Biomedical Engineering (534 citations) and Neurology (113 citations). Jillian Smith has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Crystal L. Mackall, Rosandra N. Kaplan, Rimas J. Orentas, Adrienne H. Long, Alec J. Walker, Steven L. Highfill, Yongzhi Cui, Meera Murgai, Kelsey M. Wanhainen and Jack F. Shern. Their work appears in journals such as Alzheimer s & Dementia, Neurology, Cancer Immunology Research, Nature Medicine and Journal of Clinical Pathology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Jillian Smith

Impact in

Papers in i

In The Last Decade

Jillian Smith

Jillian Smith's Hit Papers

Peers

Countries citing papers authored by Jillian Smith

Fields of papers citing papers by Jillian Smith

All Works

About Jillian Smith

Explore authors with similar magnitude of impact

Papers in